The Application of Kinesin Inhibitors in Medical Issues.

Mojgan Nejabat, Farzin Hadizadeh, Amirhossein Sahebkar
{"title":"The Application of Kinesin Inhibitors in Medical Issues.","authors":"Mojgan Nejabat, Farzin Hadizadeh, Amirhossein Sahebkar","doi":"10.2174/0127724328277623231204064614","DOIUrl":null,"url":null,"abstract":"<p><p>Kinesins are a group of motor proteins in charge of several crucial functions in the cell. These proteins often bind to microtubules and perform their functions using the energy produced by ATP hydrolysis. One function of mitotic kinesin, a subclass of kinesin that is expressed during cell division at the mitotic phase, is to create the mitotic spindle. Uncontrolled cell growth is one trait of cancerous cells. Traditional anticancer medications still used in clinics include taxanes (paclitaxel) and vinca alkaloids (vincristine, vinblastine), which interfere with microtubule dynamics. However, because non-dividing cells like post-mitotic neurons contain microtubules, unwanted side effects like peripheral neuropathy are frequently found in patients taking these medications. More than ten members of the mitotic kinesin family play distinct or complementary roles during mitosis. The mitotic kinesin family's KSP, or Eg5, is regarded as its most dramatic target protein. The current work systematically reviews the use of kinesin inhibitors in the medical field. The challenges of KSP and the practical solutions are also examined, and the outcomes of the previous works are reported. The significant gaps and shortcomings of the related works are also highlighted, which can be an onset topic for future works.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"370-378"},"PeriodicalIF":1.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Reviews in Clinical and Experimental Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0127724328277623231204064614","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Kinesins are a group of motor proteins in charge of several crucial functions in the cell. These proteins often bind to microtubules and perform their functions using the energy produced by ATP hydrolysis. One function of mitotic kinesin, a subclass of kinesin that is expressed during cell division at the mitotic phase, is to create the mitotic spindle. Uncontrolled cell growth is one trait of cancerous cells. Traditional anticancer medications still used in clinics include taxanes (paclitaxel) and vinca alkaloids (vincristine, vinblastine), which interfere with microtubule dynamics. However, because non-dividing cells like post-mitotic neurons contain microtubules, unwanted side effects like peripheral neuropathy are frequently found in patients taking these medications. More than ten members of the mitotic kinesin family play distinct or complementary roles during mitosis. The mitotic kinesin family's KSP, or Eg5, is regarded as its most dramatic target protein. The current work systematically reviews the use of kinesin inhibitors in the medical field. The challenges of KSP and the practical solutions are also examined, and the outcomes of the previous works are reported. The significant gaps and shortcomings of the related works are also highlighted, which can be an onset topic for future works.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
驱动蛋白抑制剂在医学领域的应用
驱动蛋白是一组运动蛋白,在细胞中发挥着多种重要功能。这些蛋白通常与微管结合,并利用 ATP 水解产生的能量来实现其功能。有丝分裂驱动蛋白是驱动蛋白的一个亚类,在有丝分裂阶段的细胞分裂过程中表达,其功能之一是建立有丝分裂纺锤体。不受控制的细胞生长是癌细胞的特征之一。目前仍在临床上使用的传统抗癌药物包括紫杉醇类(taxanes)和长春碱类(vinca alkaloids)(长春新碱、长春碱),它们都会干扰微管的动力学。然而,由于像有丝分裂后神经元这样的非分裂细胞含有微管,服用这些药物的患者经常会出现外周神经病变等不必要的副作用。有丝分裂驱动蛋白家族的十多个成员在有丝分裂过程中发挥着不同或互补的作用。有丝分裂驱动蛋白家族的 KSP 或 Eg5 被认为是其最引人注目的靶蛋白。目前的研究系统地回顾了驱动蛋白抑制剂在医学领域的应用。研究还探讨了 KSP 所面临的挑战和切实可行的解决方案,并报告了前人的研究成果。同时还强调了相关工作中的重大差距和不足,这些都可以成为未来工作的启动主题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.80
自引率
9.10%
发文量
55
期刊最新文献
Bigels as Novel Drug Delivery Systems: A Systematic Review on Efficiency and Influential Factors. Effectiveness and Tolerability of Various 5-Fluorouracil Formulations as Adjuvant Therapies for Vitiligo Management: A Systematic Review and Meta-Analysis. Exploring the Role of Deutetrabenazine in the Treatment of Chorea Linked with Huntington's Disease. Insights into the Pathogenesis and Treatment of Chemotherapy-Induced Neuropathy: A Focus on Oxidative Stress and Neuroinflammation. Leveraging Generative AI for Drug Safety and Pharmacovigilance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1